Abstract:
The administration of nitrofurans to livestock to treat or prevent animal diseases has been banned in the EU for the production of food of animal origin. The corresponding marker residues are tissue-related metabolites AMOZ, AHD, SEM, and AOZ. The MRPL (minimum required performance limit)/RPA (Reference point for action) was set at 1 µg kg-1 in the EU. Thus, all the laboratories involved in the control of nitrofuran metabolites must detect at least at this analytical limit of performance. The objectives of the work reported here were to evaluate the performance of ELISA kits from two different manufacturers (R-Biopharm, Germany; Europroxima, the Netherlands) for the individual screening of the four nitrofuran metabolites (AOZ, AMOZ; AHD; and SEM) in aquaculture products (fish, shrimps), and then to validate the kits according to the European Decision EC/2002/657 and to the European guideline for the validation of screening methods. The false positive rates were below 9 % for the kits from both manufacturers. The detection capabilities CCβ determined were all below the current RPA (1 µg/kg). However, regarding the updated RPA at 0.5 µg/kg that shall apply in 2022, the AMOZ and SEM kits from R-Biopharm and the SEM kit from Europroxima will not be able to reach it.
摘要:
在欧盟,已禁止将硝基呋喃用于牲畜治疗或预防动物疾病,用于生产动物源性食品。相应的标记残基是组织相关代谢物AMOZ,AHD,SEM,和AOZ。在欧盟,MRPL(最低要求性能极限)/RPA(行动参考点)设定为1µgkg-1。因此,所有参与控制硝基呋喃代谢物的实验室必须至少在此性能分析极限下进行检测。此处报告的工作目标是评估来自两个不同制造商的ELISA试剂盒的性能(R-Biopharm,德国;Euroapimena,荷兰)对四种硝基呋喃代谢物(AOZ,AMOZ;AHD;和SEM)在水产养殖产品(鱼,虾),然后根据欧洲决定EC/2002/657和欧洲筛选方法验证指南验证试剂盒。来自两个制造商的试剂盒的假阳性率均低于9%。测定的CCβ检测能力均低于目前的RPA(1μg/kg)。然而,关于将在2022年适用的0.5µg/kg的更新的RPA,R-Biopharm的AMOZ和SEM试剂盒以及Europimenta的SEM试剂盒将无法达到它。